Tiny Vesicles Drive Artery Inflammation, Plaque Instability and Calcification, and May Become Treatment Targets
A major cardiology review shows how extracellular vesicles fuel atherosclerosis, from early inflammation to calcified plaques, and could serve as biomarkers and drug targets.
Summary
Extracellular vesicles (EVs) are tiny membrane-bound packages that cells release to communicate with one another. This review in the European Heart Journal explains how EVs from endothelial cells, immune cells, platelets, red blood cells, and vascular smooth muscle cells contribute to atherosclerosis. Early on, they carry inflammatory proteins and microRNAs that impair blood vessel function, recruit immune cells, and increase oxidative stress. As plaques mature, EVs promote foam cell formation, shift smooth muscle cells into harmful states, and remodel the surrounding matrix, which can destabilize plaques. EVs also seed vascular calcification by acting as nucleation sites for mineral deposits. Because EVs circulate in blood and reflect disease processes, they may serve as biomarkers. Altering EV release or cargo, or engineering EVs for drug delivery, is proposed as a future treatment strategy.
Detailed Summary
Atherosclerosis remains a leading cause of heart attack and stroke, and it develops over decades as arteries age. Understanding how cells in the vessel wall signal to each other could reveal new ways to detect and treat it earlier. Extracellular vesicles (EVs) are one such signaling system.
This narrative review, written by cardiovascular researchers in France, the US, and China, synthesizes current knowledge on how EVs take part in atherosclerosis. It covers vesicles from endothelial cells, leukocytes, platelets, erythrocytes, and vascular smooth muscle cells (VSMCs).
The authors describe a progression. Early on, endothelial EVs carry pro-inflammatory proteins and microRNAs that impair endothelial function, promote leukocyte adhesion, and increase oxidative stress. Platelet and leukocyte EVs amplify this by driving monocyte recruitment, cytokine release, and thrombotic signaling. In maturing lesions, EVs help drive macrophage foam cell formation and push VSMCs toward synthetic or osteogenic states. Their lipid, enzyme, and nucleic acid cargo affects cholesterol handling, matrix remodeling, and apoptosis, contributing to plaque instability. EVs from VSMCs and macrophages can also nucleate hydroxyapatite, especially when rich in phosphatidylserine, annexins, or calcification-related microRNAs. Mineral imbalance, oxidative stress, and inflammation alter EV cargo to favor calcification, which stiffens arteries and can destabilize plaques.
The authors propose that EVs could serve as accessible blood biomarkers for monitoring disease and as therapeutic targets. Options include reducing EV release, changing their composition, or engineering EVs as delivery vehicles.
Caveats: this summary rests on the abstract alone. It does not show how strong the human evidence is, which findings come from animal or cell studies, or whether EV-based tests or therapies have been validated clinically. Such applications appear to remain at an early, exploratory stage.
Key Findings
- EVs from endothelial cells carry pro-inflammatory proteins and microRNAs that impair endothelial function and promote leukocyte adhesion in early atherosclerosis.
- Platelet- and leukocyte-derived EVs amplify arterial inflammation by stimulating monocyte recruitment, cytokine release, and thrombotic signaling.
- In advanced lesions, EVs promote foam cell formation and VSMC shifts toward synthetic or osteogenic states, contributing to plaque instability.
- VSMC- and macrophage-derived EVs enriched in phosphatidylserine, annexins, or specific microRNAs can nucleate hydroxyapatite and drive vascular calcification.
- EVs are proposed as circulating biomarkers and therapeutic targets or delivery vehicles for atherosclerotic disease.
Methodology
This is a narrative review in the European Heart Journal that synthesizes mechanistic and translational literature on EVs in atherosclerosis. Only the abstract was available, so details of literature search methods, study selection, and evidence grading are unknown.
Study Limitations
The abstract does not specify how much evidence comes from human studies versus preclinical models, or whether EV biomarkers have been validated for prediction or treatment decisions. Challenges such as EV isolation standardization, cargo heterogeneity, and safety of EV-based therapies are not addressed in the abstract. Conclusions here are limited to the abstract content.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: